FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311860188> ?p ?o ?g. }

• W4311860188 endingPage "874" @default.
• W4311860188 startingPage "866" @default.
• W4311860188 abstract "Vascular endothelial growth factor A (VEGF-A) has therapeutic cardiovascular effects, but delivery challenges have impeded clinical development. We report the first clinical study of naked mRNA encoding VEGF-A (AZD8601) injected into the human heart. EPICCURE (ClinicalTrials.gov: NCT03370887) was a randomized, double-blind study of AZD8601 in patients with left ventricular ejection fraction (LVEF) 30%–50% who were undergoing elective coronary artery bypass surgery. Thirty epicardial injections of AZD8601 (total 3 mg) or placebo in citrate-buffered saline were targeted to ischemic but viable myocardial regions mapped using quantitative [15O]-water positron emission tomography. Seven patients received AZD8601 and four received placebo and were followed for 6 months. There were no deaths or treatment-related serious adverse events and no AZD8601-associated infections, immune reactions, or arrhythmias. Exploratory outcomes indicated potential improvement in LVEF, Kansas City Cardiomyopathy Questionnaire scores, and N-terminal pro-B-type natriuretic peptide levels, but the study is limited in size, and significant efficacy conclusions are not possible from the dataset. Naked mRNA without lipid encapsulation may provide a safe delivery platform for introducing genetic material to cardiac muscle, but further studies are needed to confirm efficacy and safety in a larger patient pool. Vascular endothelial growth factor A (VEGF-A) has therapeutic cardiovascular effects, but delivery challenges have impeded clinical development. We report the first clinical study of naked mRNA encoding VEGF-A (AZD8601) injected into the human heart. EPICCURE (ClinicalTrials.gov: NCT03370887) was a randomized, double-blind study of AZD8601 in patients with left ventricular ejection fraction (LVEF) 30%–50% who were undergoing elective coronary artery bypass surgery. Thirty epicardial injections of AZD8601 (total 3 mg) or placebo in citrate-buffered saline were targeted to ischemic but viable myocardial regions mapped using quantitative [15O]-water positron emission tomography. Seven patients received AZD8601 and four received placebo and were followed for 6 months. There were no deaths or treatment-related serious adverse events and no AZD8601-associated infections, immune reactions, or arrhythmias. Exploratory outcomes indicated potential improvement in LVEF, Kansas City Cardiomyopathy Questionnaire scores, and N-terminal pro-B-type natriuretic peptide levels, but the study is limited in size, and significant efficacy conclusions are not possible from the dataset. Naked mRNA without lipid encapsulation may provide a safe delivery platform for introducing genetic material to cardiac muscle, but further studies are needed to confirm efficacy and safety in a larger patient pool." @default.
• W4311860188 created "2023-01-01" @default.
• W4311860188 creator A5003037617 @default.
• W4311860188 creator A5010982846 @default.
• W4311860188 creator A5019582752 @default.
• W4311860188 creator A5026529813 @default.
• W4311860188 creator A5029540294 @default.
• W4311860188 creator A5036204802 @default.
• W4311860188 creator A5037085522 @default.
• W4311860188 creator A5038218695 @default.
• W4311860188 creator A5038327639 @default.
• W4311860188 creator A5039027696 @default.
• W4311860188 creator A5051555169 @default.
• W4311860188 creator A5062282863 @default.
• W4311860188 creator A5066202291 @default.
• W4311860188 creator A5068373500 @default.
• W4311860188 creator A5070124449 @default.
• W4311860188 creator A5075290033 @default.
• W4311860188 creator A5081634170 @default.
• W4311860188 creator A5084686604 @default.
• W4311860188 creator A5091776005 @default.
• W4311860188 date "2023-03-01" @default.
• W4311860188 modified "2023-10-07" @default.
• W4311860188 title "Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting" @default.
• W4311860188 cites W2034712410 @default.
• W4311860188 cites W2044591445 @default.
• W4311860188 cites W2098419906 @default.
• W4311860188 cites W2109647832 @default.
• W4311860188 cites W2141795747 @default.
• W4311860188 cites W2152000585 @default.
• W4311860188 cites W2510379068 @default.
• W4311860188 cites W2515819079 @default.
• W4311860188 cites W2535547710 @default.
• W4311860188 cites W2556366293 @default.
• W4311860188 cites W2569712664 @default.
• W4311860188 cites W2797607167 @default.
• W4311860188 cites W2895708241 @default.
• W4311860188 cites W2903506831 @default.
• W4311860188 cites W2917369987 @default.
• W4311860188 cites W2969208689 @default.
• W4311860188 cites W3033924035 @default.
• W4311860188 cites W3100059425 @default.
• W4311860188 cites W3113178943 @default.
• W4311860188 cites W3124957780 @default.
• W4311860188 cites W4200501834 @default.
• W4311860188 cites W4205483821 @default.
• W4311860188 cites W4292341110 @default.
• W4311860188 doi "https://doi.org/10.1016/j.ymthe.2022.11.017" @default.
• W4311860188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36528793" @default.
• W4311860188 hasPublicationYear "2023" @default.
• W4311860188 type Work @default.
• W4311860188 citedByCount "4" @default.
• W4311860188 countsByYear W43118601882023 @default.
• W4311860188 crossrefType "journal-article" @default.
• W4311860188 hasAuthorship W4311860188A5003037617 @default.
• W4311860188 hasAuthorship W4311860188A5010982846 @default.
• W4311860188 hasAuthorship W4311860188A5019582752 @default.
• W4311860188 hasAuthorship W4311860188A5026529813 @default.
• W4311860188 hasAuthorship W4311860188A5029540294 @default.
• W4311860188 hasAuthorship W4311860188A5036204802 @default.
• W4311860188 hasAuthorship W4311860188A5037085522 @default.
• W4311860188 hasAuthorship W4311860188A5038218695 @default.
• W4311860188 hasAuthorship W4311860188A5038327639 @default.
• W4311860188 hasAuthorship W4311860188A5039027696 @default.
• W4311860188 hasAuthorship W4311860188A5051555169 @default.
• W4311860188 hasAuthorship W4311860188A5062282863 @default.
• W4311860188 hasAuthorship W4311860188A5066202291 @default.
• W4311860188 hasAuthorship W4311860188A5068373500 @default.
• W4311860188 hasAuthorship W4311860188A5070124449 @default.
• W4311860188 hasAuthorship W4311860188A5075290033 @default.
• W4311860188 hasAuthorship W4311860188A5081634170 @default.
• W4311860188 hasAuthorship W4311860188A5084686604 @default.
• W4311860188 hasAuthorship W4311860188A5091776005 @default.
• W4311860188 hasBestOaLocation W43118601881 @default.
• W4311860188 hasConcept C126322002 @default.
• W4311860188 hasConcept C142724271 @default.
• W4311860188 hasConcept C164705383 @default.
• W4311860188 hasConcept C167734588 @default.
• W4311860188 hasConcept C197934379 @default.
• W4311860188 hasConcept C204787440 @default.
• W4311860188 hasConcept C27081682 @default.
• W4311860188 hasConcept C2775915353 @default.
• W4311860188 hasConcept C2776820930 @default.
• W4311860188 hasConcept C2777025900 @default.
• W4311860188 hasConcept C2778198053 @default.
• W4311860188 hasConcept C535046627 @default.
• W4311860188 hasConcept C71924100 @default.
• W4311860188 hasConcept C78085059 @default.
• W4311860188 hasConceptScore W4311860188C126322002 @default.
• W4311860188 hasConceptScore W4311860188C142724271 @default.
• W4311860188 hasConceptScore W4311860188C164705383 @default.
• W4311860188 hasConceptScore W4311860188C167734588 @default.
• W4311860188 hasConceptScore W4311860188C197934379 @default.
• W4311860188 hasConceptScore W4311860188C204787440 @default.
• W4311860188 hasConceptScore W4311860188C27081682 @default.
• W4311860188 hasConceptScore W4311860188C2775915353 @default.
• W4311860188 hasConceptScore W4311860188C2776820930 @default.
• W4311860188 hasConceptScore W4311860188C2777025900 @default.

• next